Related references
Note: Only part of the references are listed.Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Sara A. Hurvitz et al.
CLINICAL CANCER RESEARCH (2012)
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
Valentina Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
Miguel Martin et al.
ONCOLOGIST (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Trastuzumab Does Not Increase the Incidence of Central Nervous System (CNS) Relapses in HER2-Positive Early Breast Cancer: The HERA Trial Experience.
B. Pestalozzi et al.
CANCER RESEARCH (2011)
HER2011: The Changing Face of HER2-Positive Breast Cancer
George W. Sledge
CLINICAL BREAST CANCER (2011)
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
Adam M. Brufsky et al.
CLINICAL CANCER RESEARCH (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Preclinical approaches to study the biology and treatment of brain metastases
William Cruz-Munoz et al.
SEMINARS IN CANCER BIOLOGY (2011)
The role of the organ microenvironment in brain metastasis
Isaiah J. Fidler
SEMINARS IN CANCER BIOLOGY (2011)
Bevacizumab Safety in Patients with Central Nervous System Metastases
Benjamin Besse et al.
CLINICAL CANCER RESEARCH (2010)
Real-time imaging reveals the single steps of brain metastasis formation
Yvonne Kienast et al.
NATURE MEDICINE (2010)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2009)
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases
Brian Leyland-Jones
JOURNAL OF CLINICAL ONCOLOGY (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genes that mediate breast cancer metastasis to the brain
Paula D. Bos et al.
NATURE (2009)
Secreted Gaussia Luciferase as a Biomarker for Monitoring Tumor Progression and Treatment Response of Systemic Metastases
Euiheon Chung et al.
PLOS ONE (2009)
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
Xiao-Feng Le et al.
CELL CYCLE (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A secreted luciferase for ex vivo monitoring of in vivo processes
Thomas Wurdinger et al.
NATURE METHODS (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain
Diane Palmieri et al.
CANCER RESEARCH (2007)
Brain metastases: The HER2 paradigm
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
H. J. Stemmler et al.
BREAST (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts
JM du Manoir et al.
CLINICAL CANCER RESEARCH (2006)
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
WL Xia et al.
ONCOGENE (2005)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
Tumor biology - Herceptin acts as an anti-angiogenic cocktail
Y Izumi et al.
NATURE (2002)
Share Paper
